| Name | Title | Contact Details |
|---|
Mokveld Valves BV is a Dutch manufacturer with a history dating back to 1922. Originally a machine repair shop, it evolved into a leader in high-pressure axial flow valve technology. The company specializes in valves designed for rapid and reliable isolation in severe-service applications, such as High-Integrity Pressure Protection Systems (HIPPS) and Emergency Shut Down (ESD) systems. Mokvelds product range includes axial flow valves, axial control valves, angle choke valves, and axial choke valves, all engineered for demanding environments. Their valves are known for features like bubble-tight bi-directional sealing and the ability to operate under full differential pressure. Mokveld serves a global customer base in the energy sector, including oil and gas production, transmission, and processing, as well as the water industry. The company is recognized for its commitment to reliability, safety, and environmental performance.
GEICO is a Maryland-based financial institution that provides personal and commercial insurance products for individuals and businesses.
DuBois Chemicals, Inc. is a prominent specialty chemical supplier with a history that dates back to 1920. Based in Hamilton, Ohio, the company is dedicated to providing innovative and economical solutions across various industries. DuBois focuses on delivering custom chemical solutions that enhance efficiency and reliability in industrial processes, emphasizing customer satisfaction and sustainability. The company offers a diverse product portfolio that includes cleaning and process solutions for general manufacturing, specialized chemicals for the pulp and paper industry, transportation cleaning solutions, and water treatment chemicals. With a significant facility in Cincinnati, Ohio, DuBois employs over 150 staff members, including scientists and customer service representatives, and has a strong sales team of over 400 representatives serving customers throughout North America. DuBois Chemicals demonstrates financial strength with revenues ranging from $100 million to $1 billion, allowing for continued investment in research and development.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.